

Investor Conference

Bonraybio Co., Ltd.

Safe Harbor Notice

- This document and relevant information herein may contain internal and external forward-looking information and constitute forward-looking statement.
- This document and relevant information may contain certain forward-looking statements. Such forward-looking statement is not actual results but only reflects the Company's estimates and expectations and is subject to inherent risks and uncertainties that could cause actual results to differ materially from such statement.
- Financial numbers in this document contains unaudited and unreviewed information. All information is for reference only.
- Any business outlook or forward-looking statement hereof reflects the Company's estimates and expectations as of now and is subject to change after this date. Unless required by applicable law, the Company undertakes no obligation to update any such information.

About Bonraybio



Founded in
2016

Headquarter
Taiwan

China / USA Subsidiary


Employee
124

RD / QC / OM / SS / MP...

Patents
109 /132

US / EU / JP / TWN / CN...

Target
IVD,MD



Market Positioning
**Male Infertility
Total Solution**



Technology

Optical / Electronic / Mechanical /
Clinical Medicine / Artificial Intelligence



Global Presence
76 countries

Global Certification




FDA



Publications

43 X1/X3/ X12
R10 /R11/ CA0



Milestone



Global Employee: **16** People

Establish

In Taichung City

- ① Prototype of X1 PRO

2016



Global Employee: **52** People

China Subsidiary

In Sichuan Ziyang City

- ① Obtained FDA/TFDA Certificate
- ② Sold to 30 Countries

2018



Global Employee: **65** People

Utilize X1 PRO

II-Generation Algorithm

- ① Be Granted 44 Patents
- ② Sold to 54 Countries

2020



Global Employee: **68** People

Sperm Separation Device

LensHooke® CA0/CA1

- ① Be Granted 60 Patents
- ② Sold to 56 Countries

2022



Global Employee: **91** People

X3 PRO / New Reagent

LensHooke® X3 PRO/R10+ / R11+

- ① Obtained 90 Patents
- ② Sold to 53 Countries
- ③ List on TWSE (Taiwan Stock Exchange) Market
- ④ Taiwan BIO Awards

2024



Global Employee: **116** People

AI-Powered Fertility Science

LensHooke® QXD/CF1/CF2

- ① Obtained 107 Patents
- ② Sold to 76 Countries

2026

2017

Global Employee: **37** People

Settle Down

In Taichung City (industrial park)

- ① Obtained CE Certificate
- ② Launched X1 PRO



2019

Global Employee: **63** People

USA Subsidiary

In Los Angeles

- ① Obtained NMPA Certificate
- ② Sold to 56 Countries



2021

Global Employee: **67** People

DNA Fragment. Solution

LensHooke® X12 PRO+R10

- ① Be Granted 49 Patents
- ② Sold to 53 Countries



2023

Global Employee: **85** People

X12 PRO (SA Function)

LensHooke® X12 PRO / CS3

- ① Be Granted 76 Patents
- ② Sold to 52 Countries
- ③ List on the OTC Stock Market
- ④ Taipei Biotech Award _ Gold
- ⑤ National Invention & Creation Award _ Silver
- ⑥ National Innovation Award



2025

Global Employee: **110** People

X12 PRO (CR0 Function)

LensHooke® X12 PRO / CR0

- ① X12 PRO launched with CR0 interpretation function at ESHRE
- ② Product certification in Canada
- ③ 93 product patents approved



Awards



2017
Reddot award winner

2022
National Invention
and Creation Award

2023
Taipei Biotech Awards
Go-Global Gold Medal Award

2023
Certificate of the
20th National Innovation Award

2024
Taiwan BIO Awards

Core Technology



Unmet Need in IVF Field



Traditional
ART Techniques



Complicate




Time Consuming



Non-Standardization



Variation



New AI
ART Techniques

Simple



Standardization




Time Saving



Accuracy



Core Patented Technology



Core Patented Technology


AIOM

Artificial Intelligence Optical Microscopic
Patent No. US 10,324,022 B2




Unique Technology

AIOM




Miniaturization
High Resolution Lens





High Integration
Integrate Computing



Artificial Intelligence
Algorithm Structure



Lens module 3.8 x 3.8 cm
Bonraybio® Micro High Resolution Lens



Stable Light



Image Capture



Auto Focus



Integration Computing



PC Integration





Stable Power



Unique Technology

Micro High Resolution Lens


Microscope



Bonraybio® Micro High Resolution Lens



Competitive Analysis of Sperm Quality Analyzer

 Conventional Manual Exam	20 steps 75 minutes	Manual Exam	Handwritten Paper Report
 Computer-Assisted Semen Analysis Technology	20 steps 75 minutes	Semi-Automated Exam	Paper Report
 LensHooke® X1 PRO LensHooke® X3 PRO LensHooke® AIOM Technology 	3 steps 2-5 minutes	Fully Automated Exam	Paper and Video Reports
	3 steps 1 minutes	Fully Automated Exam	Paper and Video Reports

Core Patented Technology

AIOM

Artificial Intelligence Optical Microscopic
Patent No. US 10,324,022 B2




SSTT

Solid Staining Transfer Technology
Patent No. PCT/US2024/034356




Solid Staining Transfer Technology

SSTT Solid Staining Transfer Technology
Save operation time by **80%**




NEW


Solid Staining
LensHooke® R10 Plus



Complex Staining
Conventional SCD
Staining Method



Competitive Analysis of Sperm DNA Fragmentation Test Kits



Conventional
TUNEL Method

3 hours

Complex Operation

Targeting **General Cells**

Compatible
with **Non-Integrated**
Flow Cytometers

Conventional
SCSA Method

3 hours

Complex Operation

Targeting **General Cells**

Compatible
with **Non-Integrated**
Flow Cytometers

Conventional
Comet Method

4 hours

Complex Operation

Targeting **General Cells**

Compatible
with **Non-Integrated**
Specialized Software

LensHooke®
Sperm DNA Fragmentation
Rate Testing

15 minutes

Simple Operation

Targeting Sperm

Compatible with
Integrated Detection
Systems

Core Patented Technology

AIOM

Artificial Intelligence Optical Microscopic
Patent No. US 10,324,022 B2



SSTT

Solid Staining Transfer Technology
Patent No. PCT/US2024/034356





LMST

Live Motile Sorting Technology
Patent No. M634293





Live Motile Sorting Technology

SSTT Live Motile Sorting Technology
Improve semen quality by **50%**





Competitive Analysis of Sperm Selection Devices

Direct Swim Up





7 steps
70 minutes

Discontinuous Density Gradients





10 steps
60 minutes

Microfluidic



4 steps
30 minutes

LensHooke® CA0




4 steps
30 minutes

Product Scope

Semen Analysis
Basic Exam



Semen Analysis
Advanced Exam



LensHooke®
Male Infertility Total Solution



Sperm
Separation



Market



Market Statistics



48,500,000

million couples

Unable to have a child



10.5%

Women **unable** to have 2nd child after 5 years of trying




40%~50%

Infertility caused by **male's** problem



Background

Birth Rate Decreases Rapidly!



Background- Taiwan




IVF Market

Strong Potential for Future Growth of IVF

Assisted Reproductive Technology Market Size and Forecast, by End-Use (Fertility clinics, Hospitals, Gynecology Centers, Feminist Health Centers, IVF Centers, Clinics, Diagnostic centers); Technology (IVF, Artificial Insemination, Frozen Embryo Replacement (FER); Surrogacy, Ovulation Induction); Product (Instrument, Accessory & Disposable, Reagents & media); Diagnosis (Ovulation Testing, Hysterosalpingography) - Growth Trends, Key Players, Regional Analysis 2026-2035

Assisted Reproductive Technology Market Outlook:

Assisted Reproductive Technology Market size was over USD 31.7 billion in 2025 and is anticipated to cross USD 62.94 billion by 2035, growing at more than 7.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of assisted reproductive technology is assessed at USD 33.73 billion.



Male Infertility Market

Male Infertility Market Size and Forecast, by Distribution Channel (Hospital Pharmacies, Retail Pharmacies & Drug Store, Online Pharmacies); Treatment; Test - Growth Trends, Key Players, Regional Analysis 2026-2035

Male Infertility Market Outlook:

Male Infertility Market size was valued at USD 4.59 billion in 2025 and is set to exceed USD 7.55 billion by 2035, expanding at over 5.1% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of male infertility is estimated at USD 4.8 billion.



Male Infertility Market-Sperm Count Test



SPERM COUNT TEST MARKET SIZE & SHARE ANALYSIS - GROWTH TRENDS AND FORECAST (2025 - 2030)

The Sperm Count Test Market Report is Segmented by Product (Semen Analyzer Systems, Home-Use Sperm Test Kits, and More), Technology (Manual Microscopy, CASA, Microfluidics-Based Counting, and More), End User (Fertility Centers, Hospitals & Urology Clinics, Home Care, and More), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Sperm Count Test Market Analysis by Mordor Intelligence

The sperm count test market size stood at USD 2.20 billion in 2025 and is forecast to reach USD 3.39 billion by 2030, advancing at a 9.10% CAGR over 2025-2030. Heightened recognition that male factors contribute to about 50% of global infertility cases fuels sustained demand, while smartphone-enabled diagnostics delivering up to 98% accuracy democratize access to fertility testing. Growing venture funding for artificial-intelligence (AI) platforms, wider reimbursement for diagnostic procedures, and employer-sponsored fertility benefits further catalyze adoption. At the same time, social stigma in emerging markets and regulatory ambiguity around digital health applications temper growth potential. Competitive rivalry is intensifying as established assisted-reproductive-technology (ART) vendors acquire niche innovators and AI-first startups secure multimillion-dollar rounds, reshaping the industry’s technology roadmap.

Key Report Takeaways

- By product category, home-use kits captured 41.3% of sperm count test market share in 2024; software and AI platforms are projected to expand at a 14.8% CAGR through 2030.
- By technology, CASA systems led with 46.5% share of the sperm count test market size in 2024, while smartphone-enabled solutions are advancing at a 16.2% CAGR over the forecast period.
- By end user, fertility centers accounted for 38.1% of the sperm count test market size in 2024; direct-to-consumer channels are poised to grow at a 15.4% CAGR to 2030.
- By geography, North America commanded 35.1% share of the sperm count test market size in 2024, whereas Asia Pacific is registering the fastest growth at an 11.4% CAGR through 2030.

Sperm Count Test Market Size and Share

Sperm Count Test Market
Market Size in USD Billion
CAGR 9.10%




Source : Mordor Intelligence



Market Overview

Study Period	2019 - 2030
Market Size (2025)	USD 2.20 Billion
Market Size (2030)	USD 3.39 Billion
Growth Rate (2025 - 2030)	9.10% CAGR
Fastest Growing Market	Asia Pacific
Largest Market	North America
Market Concentration	Medium

Major Players



*Disclaimer: Major Players sorted in no particular order

Male Infertility Market-Sperm DNA Fragmentation Testing



Sperm DNA Fragmentation Testing Market

Segments - by Product Type (Assay Kits, Reagents, Instruments, and Consumables), Technique (SCSA, TUNEL Assay, SCD, Comet Assay, and Others), Application (Male Infertility Diagnosis, IVF and ART, Research, and Others), End-User (Fertility Clinics, Hospitals, Diagnostic Laboratories, Research Institutes, and Others), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2025-2033

Sperm DNA Fragmentation Testing Market Outlook

According to our latest research, the global **sperm DNA fragmentation testing market size** reached **USD 242 million in 2024**, reflecting robust expansion driven by increasing awareness of male infertility and technological advancements in diagnostic procedures. The market is projected to grow at a **CAGR of 6.8%** from 2025 to 2033, reaching an estimated value of **USD 467 million by 2033**. This sustained growth is primarily attributed to the rising prevalence of male infertility, the growing adoption of assisted reproductive technologies (ART), and escalating demand for advanced diagnostic solutions across both developed and emerging economies.

Male Infertility Market-Sperm Separation



Sperm Separation Method Market


ID: MRFR/HC/30677-HCR | 128 Pages | Kinjoll Dey | October 2025

Sperm Separation Method Market Research Report By Separation Technique (Density Gradient Centrifugation, Swim-Up Method, Magnetic Activated Cell Sorting, Microfluidic Devices), By Application (Assisted Reproductive Technology, Genetic Studies, Contraceptive Development), By End User (Fertility Clinics, Research Laboratories, Hospitals), By Sperm Quality Assessment (Motility Assessment, Morphology Assessment, DNA Fragmentation Analysis), By Product Type (Consumables, Equipment, Reagents) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Forecast to 2035

As per MRFR analysis, the Sperm Separation Method Market was estimated at 2.066 USD Billion in 2024. The Sperm Separation Method industry is projected to grow from **2.179 USD Billion in 2025** to 3.715 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 5.48% during the forecast period 2025 - 2035.

Sperm Separation Method Market

Sperm Separation Method Market



CAGR | 5.48%

Global Market Size & CAGR


US\$ 4.637 Billions

	In Vitro Fertilization Market	Male Infertility Market	Semen Analyzer Market	Sperm DNA Fragment. Market	Sperm Seperation Market
2025 Market Size	US\$ 31.7 Billions	US\$ 4.59 Billions	US\$ 2.2 Billions	US\$ 258 Millions	US\$ 2.179 Billions
CAGR	7.1% (2026-2035)	5.1% (2026-2035)	9.1% (2025-2030)	6.8% (2025-2033)	5.48% (2025-2035)
Source	 Research Nester	 Research Nester	 Mordor Intelligence	 DATA INTELO	 MARKET RESEARCH FUTURE®

Market Positioning

LensHooke®

Male Infertility Total Solution



Product Scope

Semen Analysis
Basic Exam




LensHooke®
Male Infertility Total Solution




Sperm
Separation



Semen Analysis
Advanced Exam




Product Launch Timeline



Global Presence

 Available

76



2200+

IVF Labs or Clinics adopt
LensHooke®

America

- | | |
|-------------|---------------|
| Ecuador | Bolivia |
| Brazil | United States |
| Barberdo | Colombia |
| Panama | Uruguay |
| Canada | Peru |
| Dominican | Chile |
| Republic | Mexico |
| Puerto Rico | |
| Argentina | |

Europe

- | | | |
|-----------|-------------|----------|
| Turkey | Netherlands | Serbia |
| Denmark | Georgia | Sweden |
| Lithuania | Federation | Italy |
| Hungary | Bulgaria | Portugal |
| Spain | United | Germany |
| Croatian | Kingdom | Moldova |
| Greece | Macedonia | Moritz |
| France | Maltah | Cyprus |
| Poland | Czech | Romania |
| Russian | Republic | |

MENA

- Bahrain
Palestine
Pakistan
Israel
Iraq
Iran
Saudi Arabia
United Arab

Asia

- | | |
|----------|------------|
| Emirates | China |
| Oman | Japan |
| Kuwait | Taiwan |
| Qatar | Nepal |
| Syria | Indonesia |
| Lebanon | India |
| | Bangladesh |
| | Cambodia |
| | Thailand |


Oceania

- Malaysia
Philippines
Vietnam
Singapore
Mongolia
South Korea





Africa

- Libya
Kenya
Somalia
Mauritius
Sudan
Burkina Faso

Auto AI focus Technology



AI





LensHooke®

LensHooke®



bonraybio. 6955.TW

Created by



LensDiagnosis®



Confidential

Operating Results



Branding Strategy

Product Brand
Marketing & Sales

LenSHOOKE®
AI-Powered Fertility Science
Standardization Reliability Efficiency

LenSDiagnosis®

Corporate Brand
Design & Manufacture


bonraybio®
Technology Inside

Patent Portfolio



All
132



Issued
109



Pending
23

X1 PRO



- 003819614-0004
- EP3244250B1
- EP3222994B1
- 9003819614-0004



X12 PRO

- CN 304284876
- CN110408513B
- CN112098405B
- CN113406318B
- I699532B
- D186172
- I755755
- I572896
- I647452
- I808435
- CN 106198536
- CN 108474735

- US 9,958,665 B2
- US 9,959,621 B2
- US 10,281,386 B2
- US 9,958,658 B2
- US 9,664,611 B2
- US 10,324,022 B2
- US 10,852,290 B2
- US 10,928,378 B2
- US D858,790 S
- US 11,268,947 B2
- US 11,921,101
- US 11,899,007

CS0 / CS1



- 003819614-0003
- 006362836-0001
- 9006362836
- 9003819614-0003
- US D831,224 S
- USD912273S
- D186173
- I688759
- D202000
- 305466832S
- CN 304284890 S
- CN109943473B

Strip



- 003819614-0001
- 003819614-0002
- 9003819614-0001
- 9003819614-0002
- USD816862S
- USD816863S
- D186969
- D186174
- CN304406612S
- CN304328795S

QXA



- I740420
- US 11,754,485 B2
- CN113495136B

CS3



- EP4414076A1 (P)
- 015044528 (P)
- US20240261781A1 (P)
- 29/921193 (P)
- I866690
- D232159
- CN118465245A (P)
- CN308893228S

CR0



- M666722
- CN222979198U

R10/R10 Plus



- EP4019646A1 (P)
- US 11,644,455 B2
- US20220195492A1 (P)
- US20230251241A1 (P)
- US20230075204A1 (P)
- US20260098790A1 (P)
- CN114659868B
- CN114660059B

R11 Plus



- PCT/US2024/034356 (P)
- I775252
- I777336
- 113122401 (P)
- 114147834 (P)
- EP4019645B1
- EP4019646B1

WIPO



CA0/CA1



- EP4130228A2 (P)
- US20230031283A1 (P)
- US20240034990A1 (P)
- I856300
- M634293
- CN115701450B
- CN218561447U
- 202610560441.X

CK0



- 003824994-0001
- 9003824994-0001
- US 10,940,479 B2
- US D842,494 S
- D183283
- I620923
- CN 107966327
- CN 304326173
- EP3311753

Product Registration

													
Country	Taiwan	USA	EU	China	Canada	Japan	Australia	Indonesia	Colombia	Argentina	Brazil	Saudi Arabia	Turkey
Analyzer	X1 PRO X12 PRO X3 PRO	X1 PRO X1 PRO SE (CLIA Waiver) X12 PRO X3 PRO SE (CLIA Waiver)	X1 PRO X12 PRO X3 PRO Software: S10	X1 PRO X12 PRO	X12 PRO X3 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO	X1 PRO X12 PRO	X1 PRO
Consumables	CS0、CS1、CK0 CK1、CA0、CA1 CR0、CS3、CW0 CW1、CWA	CS0、CS1、CK0 CK1、CA0、CA1 CR0、CW0、CS3 CW1、CWA	CS0、CS1、CK0 CK1、CA0、CA1 CS3、CR0、CW0 CW1、CWA	CS0、CS1、CK0 CK1、CS3、CA0 CA1	CA0、CA1	CS0、CS1、CK0 CS3	CS0、CS1、CK0 CK1、CW0、CA0 CA1、CS3、CR0 CW1、CWA	CS0、CS1、CA0 CS3、CA1、CK0 CW0	CS0、CS1、CK0 CK1、CW0、CS3 CA0、CA1	CS、CK0、CW0 CS1、CS3	CS0、CA0	CS、CK0、CS1	CS1
Quality Control	QX0、QXA、QXB QXC	QX0、QXA、QXB、 QXC	QX0、QXA、QXB QXC			QX0、QXA	QX0、QXA、QXB	QX0、QXA	QX0、QXA、QXB	QX0、QXA	QX0	QX0	
Reagent	R10、R11 R10 Plus、R11 Plus	R10、R11 R10 Plus、R11 Plus	R10、R11 R10 Plus、R11 Plus	R10、R11			R10、R11 R10 Plus、R11 Plus	R10、R10 Plus		R10、R10 Plus R11 Plus	R10	R10	

														
Country	Malaysia	Mexico	Singapore	Israel	Russia	Kuwait	Switzerland	U.K.	South Korea	Georgia	Thailand	India	Serbia	Vietnam
Analyzer	X1 PRO X12 PRO X3 PRO	X1 PRO	X1 PRO	X1 PRO X3 PRO	X1 PRO	X1 PRO	X1 PRO X12 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO X3 PRO		X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO X3 PRO	X1 PRO X12 PRO	X1 PRO X12 PRO
Consumables	CS0、CS1、CK0 CW0、CW1 CS3、CR0	CS0、CK0	CS0、CS1、CK0 CK1、CA0、 CA1	CS1、CK0 CA0、CA1 CW0、CS3		CS1、CK0	CS0、CS1 CK0、CK1 CA0、CA1 CS3、CR0	CS0、CS1 CK0、CK1 CA0、CA1 CS3、CR0 CW0、CW1 CWA		CS1	CS1、CK0、CK1 CW0、CW1 CS3、CR0、CA0 CA1	CS1、CS3、CR0 CK0、CA0 CA1	CS1、CK0 CA0、CA1	CA0、CA1
Quality Control	QX0、QXA QXC	QX0	QX0、QXA QXB	QX0、QXA QXB		QX0、QXA	QX0、QXA QXB	QX0、QXA QXB、QXC			QX0、QXA QXB	QX0、QXA	QX0、QXA QXB	
Reagent	R10 Plus R11 Plus	R10 Plus R11 Plus					R10 R11	R10、R11 R10 Plus R11 Plus	R10 Plus R11 Plus	R10	R10、R10 Plus R11 Plus	R10、R10 Plus R11 Plus	R10	R10、R10 Plus R11 Plus

Monthly Operating Revenue - MOPS

Statement of Operating Revenue(6955 BONRAYBIO)				Unit:NTD'000		
Month	Operating Revenue			Accumulated Operating Revenue		
	Year 2026	Year 2025	Increase (Decrease) (%)	As of The End of This Month In Year 2026	The Corresponding Period In Year 2025	Increase (Decrease) (%)
05	30,038	26,673	12.62	143,321	125,144	14.52
04	28,898	27,444	5.30	113,283	98,471	15.04
03	31,098	25,867	20.22	84,385	71,027	18.81
02	26,906	23,802	13.04	53,287	45,160	18.00
01	26,381	21,358	23.52	26,381	21,358	23.52

Profit and loss statement

NT thousand

Item	Year	2026Q1		2025Q1		變動百分比
		\$	%	\$	%	
Total operating revenue		84,385	100%	71,027	100%	18.81%
Total operating costs		19,930	24%	15,678	22%	
Gross profit		64,455	76%	55,349	78%	
Selling expenses		8,178	10%	8,229	11%	
Administrative expenses		12,864	15%	11,850	17%	
R&D expenses		17,949	21%	12,530	18%	
Net operating income		25,464	30%	22,740	32%	
Non operating income and expense		2,521	3%	2,077	3%	
Profit from continuing operations before tax		27,985	33%	24,817	35%	
Total tax expense		(4,041)	(4%)	(723)	(1%)	
Profit		23,944	29%	24,094	34%	
EPS before Tax (NTD)		1.13		1.0		
EPS after Tax (NTD)		0.97		0.97		

Dividend Policy

Year Item	2023	2024	2025
EPS(NTD)	1.51	3.45	4.13
Dividend distribution			
cash dividend-NTD	0.2	1.5	1.5
stock dividends-NTD	1.0	1.0	1.5
Stock Distribution from Capital Surplus-NTD	0.5	0.5	0.75

LensHOOKE® |  **bonraybio®** Created by

THANK YOU.